Related Experiment Video
Updated: Jun 4, 2026
04:00
Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients
Published on: August 2, 2024
Periocular allergic contact dermatitis following topical Mitomycin C eye drop application
Tongabay Cumurcu1, Serpil Sener, Mufide Cavdar
1Department of Ophthalmology, School of Medicine, Inonu University, Malatya, Turkey. tongabay@superonline.com
Cutaneous and Ocular Toxicology
|February 12, 2011
Summary
Topical Mitomycin C (MMC) can cause severe ocular contact dermatitis in patients with squamous cell carcinoma. Prompt discontinuation and corticosteroid treatment resolved the dermatitis, highlighting the need for careful monitoring during MMC therapy.
Area of Science:
- Ophthalmology
- Dermatology
- Oncology
Background:
- Squamous cell carcinoma is a common malignancy affecting the ocular surface.
- Mitomycin C (MMC) is a chemotherapeutic agent used in treating ocular surface tumors.
- Surgical excision followed by topical MMC is a treatment regimen for ocular tumors.
Observation:
- A 63-year-old female presented with an extensive limbal papilliform tumor.
- The lesion was diagnosed as invasive squamous cell carcinoma.
- Post-surgical topical 0.02% Mitomycin C (MMC) was initiated.
Findings:
- The patient developed severe periorbital contact dermatitis two days after commencing topical MMC.
- Patch testing confirmed a positive reaction to MMC.
- Dermatitis resolved upon MMC discontinuation and topical corticosteroid treatment.
Implications:
- Topical MMC, while effective for ocular tumors, carries a risk of severe ocular contact dermatitis.
- Ophthalmologists should be vigilant for adverse reactions during MMC treatment.
- Early recognition and management of dermatitis are crucial for patient comfort and treatment adherence.
